7/1/2020 8:07:04 AM
Soliton Files 510(k) With FDA For RAP Device For Reduction Of Cellulite
6/26/2020 9:26:39 AM
Soliton Announces Pricing Of Underwritten Public Offering Of 4.22 Mln Shares At $8.30/shr
6/15/2020 8:06:14 AM
Soliton Reports Positive Pivotal Cellulite Clinical Trial Results
5/14/2020 7:34:43 AM
Soliton Q1 Net Loss $3.3 Mln Or $0.19/shr Vs. Net Loss $3.4 Mln Or $0.43/shr Last Year
3/11/2020 8:02:32 AM
Soliton Secures FDA Clearance Of Special 510(k) Regarding Generation II Rapid Acoustic Pulse Device
1/27/2020 8:15:46 AM
Soliton Reports Positive Data From Extended Keloid And Hypertrophic Scar Trials
12/18/2019 8:09:24 AM
Soliton Announces Completion Of Safety Testing At SGS To Support FDA Filing For Second Generation Device
12/10/2019 8:02:04 AM
Soliton Appoints Mary Stoll As Senior Director Of Clinical Development
11/21/2019 8:08:34 AM
Soliton And Emphysys Enter Into A 3-year Development Deal
11/5/2019 9:04:19 AM
Soliton Says Pivotal Cellulite Trial Has Been Completed
10/25/2019 8:11:32 AM
Soliton Reports Positive Interim Trial Results With 27% Reduction In Scar Volume From Single Non Invasive Treatment
10/10/2019 8:37:24 AM
Soliton Announces $6.25 Mln Private Placement